UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 599

Sortiert nach

Identifying Residual Nodal Disease in Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy for Breast Cancer

Annals of surgical oncology, 2019-11, Vol.26 (12), p.3794-3797

Boughey, Judy C.

2019

Volltextzugriff (PDF)

Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline

Journal of clinical oncology, 2020-06, Vol.38 (18), p.2080-2106

2020

Volltextzugriff (PDF)

The Landmark Series: Neoadjuvant Chemotherapy for Triple-Negative and HER2-Positive Breast Cancer

Annals of surgical oncology, 2021-04, Vol.28 (4), p.2111-2119

2021

Volltextzugriff (PDF)

Consensus Guidelines on Genetic` Testing for Hereditary Breast Cancer from the American Society of Breast Surgeons

Annals of surgical oncology, 2019-10, Vol.26 (10), p.3025-3031

2019

Volltextzugriff (PDF)

Identification and Resection of Clipped Node Decreases the False-negative Rate of Sentinel Lymph Node Surgery in Patients Presenting With Node-positive Breast Cancer (T0–T4, N1–N2) Who Receive Neoadjuvant Chemotherapy: Results From ACOSOG Z1071 (Alliance)

Annals of surgery, 2016-04, Vol.263 (4), p.802-807

2016

Volltextzugriff (PDF)

Localizing the Clipped Node in Patients with Node-Positive Breast Cancer Treated with Neoadjuvant Chemotherapy: Early Learning Experience and Challenges

Annals of surgical oncology, 2017-10, Vol.24 (10), p.3011-3016

2017

Volltextzugriff (PDF)

ASO Author Reflections: Low Estrogen Receptor (ER) Expression Breast Cancer Behaves More like ER Negative Disease and Influences Management

Annals of surgical oncology, 2023-10, Vol.30 (11), p.6484-6485

2023

Volltextzugriff (PDF)

DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine

The Journal of clinical investigation, 2018-06, Vol.128 (6), p.2376-2388

2018

Volltextzugriff (PDF)

First steps into synoptic operative reporting in breast cancer surgery: A journey to improve quality cancer care

Surgery, 2023-09, Vol.174 (3), p.715-716

2023

Volltextzugriff (PDF)

Association of Low Nodal Positivity Rate Among Patients With ERBB2-Positive or Triple-Negative Breast Cancer and Breast Pathologic Complete Response to Neoadjuvant Chemotherapy

JAMA surgery, 2018-12, Vol.153 (12), p.1120

2018

Volltextzugriff (PDF)

Neoadjuvant Chemotherapy Use in Breast Cancer is Greatest in Excellent Responders: Triple-Negative and HER2+ Subtypes

Annals of surgical oncology, 2018-08, Vol.25 (8), p.2241-2248

2018

Volltextzugriff (PDF)

Neoadjuvant Chemotherapy and Nodal Response Rates in Luminal Breast Cancer: Effects of Age and Tumor Ki67

Annals of surgical oncology, 2022-09, Vol.29 (9), p.5747-5756

2022

Volltextzugriff (PDF)

Oncologic Outcomes of Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy for Node-Positive Breast Cancer

Annals of surgical oncology, 2020-11, Vol.27 (12), p.4795-4801

2020

Volltextzugriff (PDF)

ASO Author Reflections: Evolving Paradigms in Axillary Management for Breast Cancer: Insights from the ISPY-2 Neoadjuvant Chemotherapy Trial

Annals of surgical oncology, 2024-07

2024

Volltextzugriff (PDF)

ASO Author Reflections: Extreme Early Adoption—The Omission of Axillary Lymph Node Dissection is Being Adopted into Practice Before Clinical Trial Data are Available: Where Might this Lead?

Annals of surgical oncology, 2024-07

2024

Volltextzugriff (PDF)

A comprehensive analysis of breast cancer microbiota and host gene expression

PloS one, 2017-11, Vol.12 (11), p.e0188873-e0188873

2017

Volltextzugriff (PDF)

Breast Cancer-Related Lymphedema Risk is Related to Multidisciplinary Treatment and Not Surgery Alone: Results from a Large Cohort Study

Annals of surgical oncology, 2017-10, Vol.24 (10), p.2972-2980

2017

Volltextzugriff (PDF)

Local Recurrence After Breast-Conserving Therapy in Patients With Multiple Ipsilateral Breast Cancer: Results From ACOSOG Z11102 (Alliance)

Journal of clinical oncology, 2023-06, Vol.41 (17), p.3184-3193

2023

Volltextzugriff (PDF)

ASO Author Reflections: In an Era of De-escalation, Are We Still Doing Too Much for Stage 0 Breast Cancer?

Annals of surgical oncology, 2022-11, Vol.29 (12), p.7713-7714

2022

Volltextzugriff (PDF)

The Clinical Significance of Breast-only and Node-only Pathologic Complete Response (pCR) After Neoadjuvant Chemotherapy (NACT): A Review of 20,000 Breast Cancer Patients in the National Cancer Data Base (NCDB)

Annals of surgery, 2018-10, Vol.268 (4), p.591-601

2018

Volltextzugriff (PDF)

Tumor Biology Correlates With Rates of Breast-Conserving Surgery and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer: Findings From the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial

Annals of surgery, 2014-10, Vol.260 (4), p.608-616

2014

Volltextzugriff (PDF)

Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial

JAMA : the journal of the American Medical Association, 2013-10, Vol.310 (14), p.1455

2013

Volltextzugriff (PDF)

Locoregional Management of Multiple Ipsilateral Breast Cancers: A Review

Clinical breast cancer, 2024-08, Vol.24 (6), p.473-480

2024

Volltextzugriff (PDF)

Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2 -positive breast cancer (Z1041): a randomised, controlled, phase 3 trial

The lancet oncology, 2013-12, Vol.14 (13), p.1317-1325

2013

Volltextzugriff (PDF)

Factors Associated With Lymphedema in Women With Node-Positive Breast Cancer Treated With Neoadjuvant Chemotherapy and Axillary Dissection

JAMA surgery, 2019-09, Vol.154 (9), p.800

2019

Volltextzugriff (PDF)

1 – 25 von 599

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(541)
Mit Volltextzugriff
(558)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Identifying Residual Nodal Disease in Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy for Breast Cancer

Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline

The Landmark Series: Neoadjuvant Chemotherapy for Triple-Negative and HER2-Positive Breast Cancer

Consensus Guidelines on Genetic` Testing for Hereditary Breast Cancer from the American Society of Breast Surgeons

Identification and Resection of Clipped Node Decreases the False-negative Rate of Sentinel Lymph Node Surgery in Patients Presenting With Node-positive Breast Cancer (T0–T4, N1–N2) Who Receive Neoadjuvant Chemotherapy: Results From ACOSOG Z1071 (Alliance)

Localizing the Clipped Node in Patients with Node-Positive Breast Cancer Treated with Neoadjuvant Chemotherapy: Early Learning Experience and Challenges

ASO Author Reflections: Low Estrogen Receptor (ER) Expression Breast Cancer Behaves More like ER Negative Disease and Influences Management

DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine

First steps into synoptic operative reporting in breast cancer surgery: A journey to improve quality cancer care

Association of Low Nodal Positivity Rate Among Patients With ERBB2-Positive or Triple-Negative Breast Cancer and Breast Pathologic Complete Response to Neoadjuvant Chemotherapy

Neoadjuvant Chemotherapy Use in Breast Cancer is Greatest in Excellent Responders: Triple-Negative and HER2+ Subtypes

Neoadjuvant Chemotherapy and Nodal Response Rates in Luminal Breast Cancer: Effects of Age and Tumor Ki67

Oncologic Outcomes of Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy for Node-Positive Breast Cancer

ASO Author Reflections: Evolving Paradigms in Axillary Management for Breast Cancer: Insights from the ISPY-2 Neoadjuvant Chemotherapy Trial

ASO Author Reflections: Extreme Early Adoption—The Omission of Axillary Lymph Node Dissection is Being Adopted into Practice Before Clinical Trial Data are Available: Where Might this Lead?

A comprehensive analysis of breast cancer microbiota and host gene expression

Breast Cancer-Related Lymphedema Risk is Related to Multidisciplinary Treatment and Not Surgery Alone: Results from a Large Cohort Study

Local Recurrence After Breast-Conserving Therapy in Patients With Multiple Ipsilateral Breast Cancer: Results From ACOSOG Z11102 (Alliance)

ASO Author Reflections: In an Era of De-escalation, Are We Still Doing Too Much for Stage 0 Breast Cancer?

The Clinical Significance of Breast-only and Node-only Pathologic Complete Response (pCR) After Neoadjuvant Chemotherapy (NACT): A Review of 20,000 Breast Cancer Patients in the National Cancer Data Base (NCDB)

Tumor Biology Correlates With Rates of Breast-Conserving Surgery and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer: Findings From the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial

Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial

Locoregional Management of Multiple Ipsilateral Breast Cancers: A Review

Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2 -positive breast cancer (Z1041): a randomised, controlled, phase 3 trial

Factors Associated With Lymphedema in Women With Node-Positive Breast Cancer Treated With Neoadjuvant Chemotherapy and Axillary Dissection

Suchergebnisse filtern